Filtered By:
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 3041 results found since Jan 2013.
Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020-2021
We described the epidemiology and clinical course of patients who had invasive pneumococcal disease (IPD) and temporally associated SARS-CoV-2 infections in Alaska, USA, during January 1, 2020-December 23, 2021. Of 271 patients who had laboratory-confirmed IPD, 55 (20%) had a positive SARS-CoV-2 test result. We observed no major differences in age, race, sex, or underlying medical conditions among IPD patients with and without SARS-CoV-2. However, a larger proportion of IPD patients with SARS-CoV-2 died (16%, n = 9) than for those with IPD alone (4%, n = 9) (p<0.01). IPD patients with SARS-CoV-2 were also more likely to...
Source: Emerging Infectious Diseases - July 28, 2023 Category: Infectious Diseases Authors: Katherine Newell Marc Fischer Stephanie Massey Laurie Orell Jonathan Steinberg Megan Tompkins Louisa Castrodale Joseph McLaughlin Source Type: research
Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study
CONCLUSION: In this high-risk population, no statistically significant incremental effect of a PPV23 booster at 18-30 months was observed against hospitalised all-cause pneumonia or the more specific outcome of presumptive pneumococcal pneumonia. Confounding by indication may explain the slight trend towards an increased risk against all-cause pneumonia. Larger studies with better control of confounding are needed to further inform PPV23 vaccination.PMID:37507273 | DOI:10.1016/j.vaccine.2023.07.042
Source: Vaccine - July 28, 2023 Category: Allergy & Immunology Authors: Alamgir Kabir Deborah Randall Anthony T Newall Hannah C Moore Sanjay Jayasinghe Parveen Fathima Bette Liu Peter McIntyre Heather F Gidding Source Type: research
Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020-2021
We described the epidemiology and clinical course of patients who had invasive pneumococcal disease (IPD) and temporally associated SARS-CoV-2 infections in Alaska, USA, during January 1, 2020-December 23, 2021. Of 271 patients who had laboratory-confirmed IPD, 55 (20%) had a positive SARS-CoV-2 test result. We observed no major differences in age, race, sex, or underlying medical conditions among IPD patients with and without SARS-CoV-2. However, a larger proportion of IPD patients with SARS-CoV-2 died (16%, n = 9) than for those with IPD alone (4%, n = 9) (p<0.01). IPD patients with SARS-CoV-2 were also more likely to...
Source: Emerging Infectious Diseases - July 28, 2023 Category: Infectious Diseases Authors: Katherine Newell Marc Fischer Stephanie Massey Laurie Orell Jonathan Steinberg Megan Tompkins Louisa Castrodale Joseph McLaughlin Source Type: research
Influenza and pneumococcal vaccination coverage and associated factors in patients hospitalized with acute exacerbations of COPD in China: Findings from the real-world data
CONCLUSIONS: Influenza and pneumococcal vaccination coverage are extremely low. Urgent measures are necessary to increase vaccination coverage among inpatients with AECOPD in China.PMID:37488669 | DOI:10.1097/CM9.0000000000002790
Source: Chinese Medical Journal - July 24, 2023 Category: General Medicine Authors: Ruoxi He Xiaoxia Ren Ke Huang Jieping Lei Hongtao Niu Wei Li Fen Dong Baicun Li Ye Wang Ting Yang Chen Wang Source Type: research
Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial
CONCLUSION: Even after PCV10 or PCV13 vaccination, children living in a high-risk setting such as PNG continue to experience high levels of pneumococcal colonization, including carriage of highly antimicrobial-resistant PCV serotypes. The study is registered with ClinicalTrials.gov (CTN NCT01619462).PMID:37479616 | DOI:10.1016/j.vaccine.2023.07.026
Source: Vaccine - July 21, 2023 Category: Allergy & Immunology Authors: Tilda Orami Celestine Aho Rebecca L Ford William S Pomat Andrew Greenhill Lea-Ann Kirkham Geraldine Masiria Birunu Nivio Kathryn J Britton Peter Jacoby Peter C Richmond Anita H J van den Biggelaar Deborah Lehmann Source Type: research
